Westerkirk Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.8M Sell
12,807
-392
-3% -$397K 1.27% 16
2025
Q4
$14.2M Buy
13,199
+2,313
+21% +$2.21M 1.38% 13
2025
Q3
$8.31M Sell
10,886
-1,319
-11% -$982K 0.95% 18
2025
Q2
$9.51M Buy
+12,205
New +$9.48M 1.17% 15

Other funds holding LLY

Westerkirk Capital's LLY Position: Q1 2026 in Review

Westerkirk Capital reduced its Eli Lilly (LLY) stake by 3% in Q1 2026, selling an estimated $397K and leaving 12,807 shares worth $11.8M. The position accounts for 1.27% of the portfolio, ranked #16.

Westerkirk Capital first reported a position in LLY in Q2 2025 and has held it in 4 quarters since. The position peaked at $14.2M in Q4 2025. 4,356 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Westerkirk Capital held 12,807 shares of Eli Lilly worth $11.8M as of Q1 2026.
  • Westerkirk Capital sold 392 Eli Lilly shares in Q1 2026, an estimated $397K.
  • Eli Lilly made up 1.27% of Westerkirk Capital's portfolio in Q1 2026, its #16 holding.
  • Westerkirk Capital first reported a position in Eli Lilly in Q2 2025 and has held it in 4 quarters since.
  • Westerkirk Capital's Eli Lilly position peaked at $14.2M in Q4 2025.
  • 4,356 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Westerkirk Capital's 13F filing for Q1 2026, filed 14 May 2026.